OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: OraSure develops, manufactures, and markets oral fluid diagnostic products (including HIV and Hepatitis C tests), specimen collection devices, and cryosurgical systems for wart removal. Products are sold globally to clinical laboratories, hospitals, government agencies, and retail markets.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Trends: Total revenues for the nine months ended September 30, 2010, remained flat at $56.2 million compared to $56.1 million in the prior year. For the third quarter, revenues decreased 12% to $19.0 million from $21.6 million.
• Profitability: The company reported a net income of $0.27 million for the third quarter of 2010, compared to a net income of $1.80 million in the same period of 2009. For the nine-month period, the net loss narrowed to $2.47 million from $4.98 million in 2009. The 2009 loss included a $3.0 million non-cash impairment charge for patent and product rights, which did not recur in 2010.
• Market Performance:
  • Infectious Disease: Sales decreased 20% in Q3 and 9% for the nine months, driven by reduced public health funding and lower international sales (down 69% in Q3).
  • Cryosurgical Systems: Sales increased 12% in Q3 and 18% for the nine months, primarily due to growth in the domestic professional market.
  • Licensing: Licensing and product development revenues increased 125% for the nine months to $3.52 million, largely due to $2.0 million in milestone payments from Merck regarding the OraQuick HCV test.
• Cash Flow: Net cash provided by operating activities decreased significantly to $0.24 million for the nine months ended September 30, 2010, compared to $2.69 million in the prior year period. This was due to a net loss offset by non-cash stock-based compensation and depreciation, partially negated by a $3.8 million decrease in accrued expenses (payments of 2009 royalties and bonuses).

Guidance, Outlook, and Risks

• Regulatory Developments:
  • OraQuick HCV: The FDA approved the test for venous whole blood in June 2010. A PMA supplement for fingerstick whole blood was filed in July 2010 and is under review. The oral fluid claim submission is delayed pending further FDA discussions. CLIA waiver studies are ongoing.
  • OraQuick HIV OTC: Final label validation data and an Investigational Device Exemption (IDE) request were submitted to the FDA in October 2010. Final clinical testing is expected to commence upon approval.
• Manufacturing: Automated manufacturing equipment for the OraQuick HIV test was validated and approved by the FDA. Full conversion to automated manufacturing is expected in the fourth quarter of 2010, anticipated to lower costs and increase capacity.
• Liquidity: The company holds $73.7 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations for at least the next twelve months. A $10 million credit facility with Comerica Bank matures in June 2011; the remaining balance of $7.9 million is classified as a current liability.
• Risks:
  • Economic Conditions: Continued economic downturn and reduced state/local government funding may adversely affect sales, particularly in the infectious disease and substance abuse testing markets.
  • Competition: Intense competition in HIV testing, including lower-priced blood tests and potential new oral fluid technologies from competitors.
  • Supply Chain: Reliance on sole-source providers for critical components (e.g., HIV peptides) creates supply risk.
  • Distributor Dependence: Significant reliance on distributors (e.g., SSL International, Genomma) for international sales; SSL is currently being acquired by Reckitt Benckiser, requiring contract renegotiation.

Investor Verification Checklist

• Debt Maturity: Verify the status of the $7.9 million Comerica Bank loan maturing in June 2011 and compliance with financial covenants (quick ratio, liquidity, tangible net worth).
• Regulatory Approvals: Monitor the FDA's decision on the OraQuick HCV fingerstick whole blood PMA supplement and the timeline for the oral fluid claim submission.
• International Sales: Assess the impact of reduced government funding and price competition on international HIV testing revenues, which declined significantly (69% in Q3).
• Distributor Contracts: Confirm the outcome of contract negotiations with SSL International following its acquisition by Reckitt Benckiser.
• Manufacturing Transition: Track the successful conversion to automated manufacturing for the OraQuick HIV test in Q4 2010 and its impact on cost of goods sold.